Impact of vaccinating boys and men against HPV in the United States.

We assessed the public health impact and value of vaccinating boys and men with the quadrivalent HPV vaccine in the United States. We used mathematical population models, accounting for both the direct and indirect protective effects of vaccination. Inputs for the models were obtained from public data sources, published literature, and analyses of clinical trial data. Compared with a program of vaccinating girls and women only, including boys and men 9-26 years of age would further decrease the cumulative mean number of genital wart cases, cervical intraepithelial neoplasia 2/3 cases, cancer cases, and cancer deaths by 5,146,000, 708,000, 116,000, and 40,000, respectively, within 100 years. The mean cost-effectiveness ratio (2008 US $) of this strategy was $25,700 (range: 13,600-48,800) per QALY gained if vaccination protects against all HPV 6/11/16/18-associated diseases, and $69,000 (range: 37,700-152,300)/QALY if it only protects against diseases currently in the vaccine indication. Vaccinating boys and men age 9-26 against all HPV 6/11/16/18-associated diseases provides substantial public health benefits and is cost-effective at commonly cited thresholds.

[1]  Hadi Dowlatabadi,et al.  Sensitivity and Uncertainty Analysis of Complex Models of Disease Transmission: an HIV Model, as an Example , 1994 .

[2]  Gillian D. Sanders,et al.  Cost Effectiveness of a Potential Vaccine for Human papillomavirus , 2003, Emerging infectious diseases.

[3]  J D Graham,et al.  Modeling for health care and other policy decisions: uses, roles, and validity. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  Elamin H Elbasha,et al.  Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. , 2006, Epidemiologic reviews.

[5]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[6]  E. Dasbach,et al.  The health and economic burden of genital warts in a set of private health plans in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Wright,et al.  Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. , 2002, JAMA.

[8]  J. Nelson,et al.  Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. , 2009, American journal of public health.

[9]  R. Berkowitz,et al.  Quality of life in long-term cervical cancer survivors. , 2005, Gynecologic oncology.

[10]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[11]  Erik J. Dasbach,et al.  Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.

[12]  Christophe Fraser,et al.  Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. , 2007, Vaccine.

[13]  M. Meltzer,et al.  Cost-effectiveness of hepatitis B vaccination of prison inmates. , 2002, Vaccine.

[14]  S. Franceschi,et al.  Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.

[15]  D. Ekwueme,et al.  Cost-effectiveness of Human Papillomavirus Vaccination in the United States , 2008, Emerging infectious diseases.

[16]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[17]  S. Stokley,et al.  National, state, and local area vaccination coverage among adolescents aged 13-17 years--United States, 2008. , 2009, MMWR. Morbidity and mortality weekly report.

[18]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[19]  E. Myers,et al.  Abnormal Outcomes Following Cervical Cancer Screening: Event Duration and Health Utility Loss , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  G. Sanders,et al.  Evaluating Human Papillomavirus Vaccination Programs , 2004, Emerging infectious diseases.

[21]  Shalini L Kulasingam,et al.  Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. , 2003, JAMA.

[22]  E. Dasbach,et al.  A Multi-Type HPV Transmission Model , 2008, Bulletin of mathematical biology.

[23]  H. Hethcote,et al.  An age-structured model for pertussis transmission. , 1997, Mathematical biosciences.

[24]  S. Goldie,et al.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States , 2009, BMJ : British Medical Journal.

[25]  W. Gerth,et al.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  H. Chesson,et al.  The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. , 2008, Vaccine.

[27]  K. Holmes,et al.  Epidemiology of genital human papillomavirus infection. , 1988, Epidemiologic reviews.

[28]  J. Ferlay,et al.  Cancer and infection: estimates of the attributable fraction in 1990. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  Sue J Goldie,et al.  Health and economic implications of HPV vaccination in the United States. , 2008, The New England journal of medicine.

[30]  F Reed Johnson,et al.  Modeling for health care and other policy decisions: uses, roles, and validity. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  E. Dasbach,et al.  Age-based programs for vaccination against HPV. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[32]  Jonathan P Lindman,et al.  Use of the Pediatric Quality of Life Inventory to Assess the Health-Related Quality of Life in Children with Recurrent Respiratory Papillomatosis , 2005, The Annals of otology, rhinology, and laryngology.

[33]  S. Goldie,et al.  The economic burden of noncervical human papillomavirus disease in the United States. , 2008, American journal of obstetrics and gynecology.

[34]  A. Rosen,et al.  Patient adherence: a blind spot in cost-effectiveness analyses? , 2009, The American journal of managed care.

[35]  D. Fryback,et al.  Toward consistency in cost-utility analyses: using national measures to create condition-specific values. , 1998, Medical care.